1. A 54-year-old woman with type 2 diabetes and established atherosclerotic cardiovascular disease is on high-intensity rosuvastatin 40 mg daily. Her LDL-C remains at 102 mg/dL. Her cardiologist adds ezetimibe 10 mg daily. Six weeks later her LDL-C is 78 mg/dL — an additional 24% reduction beyond the statin alone. Which of the following best explains the pharmacological mechanism responsible for this additive LDL-C lowering?
A) Ezetimibe inhibits hepatic HMG-CoA reductase at a site distinct from the statin binding domain, producing complementary blockade of the rate-limiting step in hepatic cholesterol biosynthesis and doubling the inhibitory signal on the mevalonate pathway
B) Statin-mediated reduction in hepatic intracellular cholesterol activates SREBP-2 (sterol regulatory element-binding protein 2), upregulating LDL receptor expression and increasing hepatic demand for exogenous cholesterol; ezetimibe blocks NPC1L1 (Niemann-Pick C1-like 1 protein) on the intestinal brush border, reducing the cholesterol supply available to meet this demand and forcing the liver to upregulate LDL receptors further to clear LDL-C from plasma
C) Ezetimibe inhibits PCSK9 secretion from intestinal enterocytes, preventing PCSK9-mediated LDL receptor degradation at the intestinal wall and preserving a population of intestinal LDL receptors that clear remnant lipoproteins independently of hepatic receptor activity
D) Rosuvastatin upregulates intestinal NPC1L1 expression as a compensatory response to reduced hepatic cholesterol synthesis; ezetimibe specifically counters this statin-induced intestinal upregulation, blocking the compensatory increase in cholesterol absorption that would otherwise blunt LDL-C lowering
E) Ezetimibe activates LXR (liver X receptor) in hepatocytes, increasing transcription of the ABCA1 transporter and accelerating reverse cholesterol transport; the resulting increase in HDL-C indirectly lowers LDL-C by competing for the same apolipoprotein B-containing lipoprotein clearance pathways
ANSWER: B
Rationale:
When statin-mediated HMG-CoA reductase inhibition reduces intracellular hepatic cholesterol, the cell responds by activating SREBP-2, which drives upregulation of both LDL receptor expression and HMG-CoA reductase itself. The increased LDL receptor density on hepatocyte surfaces enhances hepatic demand for exogenous cholesterol — including cholesterol delivered from the intestine. This compensatory demand partially blunts the LDL-C lowering achieved by statin monotherapy, as the liver draws more cholesterol from intestinal sources to meet its needs. Ezetimibe, by selectively blocking NPC1L1 on the intestinal brush-border membrane, reduces the supply of dietary and biliary cholesterol available to the liver. Deprived of this intestinal supply, the liver must upregulate LDL receptors further to clear LDL-C from plasma, amplifying the receptor-mediated clearance initiated by the statin. This complementary dual attack — statin suppressing synthesis and driving SREBP-2-mediated receptor upregulation, ezetimibe reducing intestinal cholesterol delivery — is the mechanistic basis for the approximately 15–25% additional LDL-C reduction ezetimibe produces on top of statin therapy.
Option A: Option A is incorrect. Ezetimibe has no activity at HMG-CoA reductase. Its sole molecular target is NPC1L1 on the intestinal brush-border membrane. Describing ezetimibe as a secondary HMG-CoA reductase inhibitor is a fundamental mechanistic error.
Option C: Option C is incorrect. Ezetimibe does not inhibit PCSK9 secretion at any site. PCSK9 inhibition is the mechanism of the monoclonal antibodies evolocumab and alirocumab and the siRNA agent inclisiran. Ezetimibe has no pharmacological activity at PCSK9 and does not affect LDL receptor degradation through this pathway.
Option D: Option D is incorrect. Statins do not upregulate intestinal NPC1L1 expression as a compensatory mechanism. The compensatory response to statin-induced intracellular cholesterol depletion is hepatic — specifically SREBP-2 activation with LDL receptor and HMG-CoA reductase upregulation. Intestinal NPC1L1 upregulation by statins is not established pharmacology.
Option E: Option E is incorrect. Ezetimibe does not activate LXR or increase ABCA1 expression. LXR agonism and ABCA1 upregulation with enhanced reverse cholesterol transport are associated with investigational LXR agonists and, to a degree, with niacin. Ezetimibe's mechanism is restricted entirely to NPC1L1 inhibition at the intestinal brush border.
2. A 67-year-old man with heterozygous familial hypercholesterolemia (HeFH) and prior myocardial infarction has an LDL-C of 118 mg/dL on maximally tolerated rosuvastatin 20 mg plus ezetimibe. His cardiologist decides to add a PCSK9 inhibitor. The patient reports severe needle phobia and asks about options. Which of the following correctly characterizes the available PCSK9 inhibitor agents and their administration schedules in a way that directly addresses this patient's concern?
A) Evolocumab and alirocumab are both administered as monthly intravenous infusions titrated to LDL-C response; inclisiran is a subcutaneous injection given every two weeks for the first three months and then monthly, making it the preferred option for needle-phobic patients due to its lower injection frequency compared to the monoclonal antibodies
B) Evolocumab is administered as a subcutaneous injection every two weeks or once monthly at a higher dose; alirocumab is administered subcutaneously every two weeks; neither agent has a monthly option, but inclisiran — a subcutaneous siRNA agent given at initiation, at three months, and then every six months — offers the least frequent injection schedule of any approved PCSK9 inhibitor and is the most appropriate option for a needle-phobic patient
C) Inclisiran is an intravenous monoclonal antibody administered every six months in an office setting; evolocumab and alirocumab are subcutaneous self-injections given every two weeks; for a needle-phobic patient, inclisiran is preferred because it eliminates self-injection entirely and is administered by a healthcare provider during scheduled visits
D) All three approved PCSK9 inhibitors — evolocumab, alirocumab, and inclisiran — are available as subcutaneous self-injections; evolocumab and alirocumab are administered every two weeks, while inclisiran is administered at day 1, month 3, and every six months thereafter, making inclisiran the option with the fewest total injections per year and the most appropriate choice for a needle-phobic patient who must self-inject
E) Evolocumab is the only PCSK9 inhibitor with an FDA-approved every-six-month dosing option; alirocumab and inclisiran are both administered monthly; for a needle-phobic patient, evolocumab 420 mg administered every six months via a prefilled autoinjector is preferred over the other agents
ANSWER: D
Rationale:
All three currently approved PCSK9-targeting agents are administered subcutaneously, but their mechanisms and dosing frequencies differ substantially. Evolocumab (a fully human monoclonal antibody) is approved at 140 mg subcutaneously every two weeks or 420 mg once monthly. Alirocumab (a humanized monoclonal antibody) is approved at 75 mg or 150 mg subcutaneously every two weeks, with a 300 mg once-monthly option available. Inclisiran is an siRNA (small interfering RNA) agent that silences PCSK9 mRNA in hepatocytes; it is approved at 284 mg subcutaneously administered on day 1, at month 3, and then every six months thereafter — yielding only two injections per year during maintenance. For a needle-phobic patient who requires PCSK9 inhibition and must receive subcutaneous injections, inclisiran's schedule of two injections per year (after the initial loading doses) represents the fewest total injections of any approved agent and directly addresses the patient's concern by minimizing injection frequency. Inclisiran is typically administered in a clinical setting by a healthcare provider, which may offer additional reassurance. option states that neither evolocumab nor alirocumab has a monthly option — this is inaccurate. Evolocumab 420 mg monthly and alirocumab 300 mg monthly are both approved dosing regimens. The core answer about inclisiran's minimal injection frequency is correct, but the premise regarding the monoclonal antibodies contains a factual error that makes this option unreliable. option. Its approved schedules are every two weeks (140 mg) or once monthly (420 mg). The every-six-month schedule belongs to inclisiran, not evolocumab.
Option A: Option A is incorrect. Neither evolocumab nor alirocumab is administered intravenously. Both are subcutaneous injections. Inclisiran is not given every two weeks; its maintenance schedule is every six months, not monthly.
Option B: Option B is incorrect in one key detail. While the inclisiran schedule and the subcutaneous route for all agents are correctly described, the
Option C: Option C is incorrect. Inclisiran is not an intravenous monoclonal antibody. It is a subcutaneous siRNA agent. The description of inclisiran's mechanism and route is fundamentally wrong, even though the six-month interval is correct.
Option E: Option E is incorrect. Evolocumab does not have an every-six-month dosing
3. A 61-year-old man with prior myocardial infarction and peripheral arterial disease has an LDL-C of 88 mg/dL on high-intensity rosuvastatin 40 mg plus ezetimibe 10 mg. His cardiologist is considering adding evolocumab. He asks whether the FOURIER trial supports this decision given that the patient's LDL-C is already below 100 mg/dL. Which of the following correctly applies FOURIER trial evidence to this clinical scenario?
A) FOURIER enrolled 27,564 patients with established ASCVD on optimized background statin therapy, with a median baseline LDL-C of 92 mg/dL; evolocumab reduced the primary composite cardiovascular endpoint by a relative 15% and lowered median on-treatment LDL-C to 30 mg/dL, with benefit consistent across the enrolled LDL-C range and no safety signal at achieved LDL-C below 20 mg/dL — directly supporting addition of evolocumab in this patient who remains above guideline targets of less than 70 mg/dL (or less than 55 mg/dL for very high risk) despite maximal oral therapy
B) FOURIER demonstrated that cardiovascular benefit from evolocumab was restricted to patients with baseline LDL-C above 100 mg/dL at enrollment; patients with baseline LDL-C below 100 mg/dL showed no statistically significant reduction in the primary composite endpoint, making evolocumab pharmacologically irrational in this patient whose LDL-C of 88 mg/dL falls below the efficacy threshold established in the trial
C) FOURIER enrolled only statin-naive patients to establish a clean LDL-C baseline; the trial does not apply to patients already on combination statin plus ezetimibe therapy because the background regimen in this patient exceeds the lipid-lowering intensity studied in FOURIER, and extrapolating the trial results to a more aggressively treated population is not supported by the evidence
D) FOURIER demonstrated a statistically significant reduction in the secondary composite endpoint of cardiovascular death, myocardial infarction, or stroke, but the primary composite endpoint — which included hospitalization for unstable angina and coronary revascularization — did not reach statistical significance; the trial therefore supports evolocumab only for hard endpoint prevention, not for the broader primary composite used in routine cardiovascular risk assessment
E) FOURIER demonstrated cardiovascular benefit exclusively in the subgroup of patients with prior myocardial infarction; patients whose qualifying ASCVD event was peripheral arterial disease or prior stroke showed no significant reduction in the primary endpoint, and the trial does not support evolocumab addition in patients whose primary ASCVD manifestation is peripheral arterial disease
ANSWER: A
Rationale:
The FOURIER trial enrolled 27,564 patients with established atherosclerotic cardiovascular disease — defined as prior myocardial infarction, prior stroke, or symptomatic peripheral arterial disease — who were on optimized background statin therapy with LDL-C of 70 mg/dL or above at baseline. The median baseline LDL-C was 92 mg/dL, meaning a substantial portion of the enrolled population had baseline LDL-C in the range of this patient. Evolocumab reduced LDL-C by approximately 59%, achieving a median on-treatment LDL-C of 30 mg/dL. The primary composite endpoint — cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization — was reduced by a relative 15% (9.8% vs. 11.3%, p<0.001). Cardiovascular benefit was consistent across subgroups including baseline LDL-C strata, and no safety signal was identified at achieved LDL-C levels below 20 mg/dL. Current ACC/AHA guidelines support LDL-C targets of less than 70 mg/dL for high-risk ASCVD and less than 55 mg/dL for very high-risk ASCVD; this patient at 88 mg/dL on maximal oral therapy remains above both thresholds, and FOURIER directly supports evolocumab addition.
Option B: Option B is incorrect. FOURIER did not establish an LDL-C threshold below which benefit disappears. The trial enrolled patients with LDL-C of 70 mg/dL or above, and benefit was consistent across the enrolled range. The "lower is better" principle operates continuously — there is no cutoff at 100 mg/dL beyond which further LDL-C reduction loses cardiovascular benefit in this population.
Option C: Option C is incorrect. FOURIER enrolled patients on optimized background statin therapy — not statin-naive patients. Approximately 69% of enrollees were on high-intensity statins. The trial directly and specifically studied evolocumab added to existing statin therapy, which is exactly the clinical scenario presented.
Option D: Option D is incorrect. FOURIER demonstrated statistically significant reduction in the primary composite endpoint (p<0.001), not only in secondary endpoints. The primary endpoint did reach statistical significance; the nuance is that cardiovascular mortality alone was not significantly reduced, but that does not mean the primary composite failed.
Option E: Option E is incorrect. FOURIER explicitly enrolled patients with peripheral arterial disease as a qualifying ASCVD event, and the trial was not limited to post-MI patients. Benefit was assessed in the overall ASCVD population; restricting the indication to post-MI patients only misrepresents the trial's enrollment criteria and conclusions.
4. A 29-year-old woman with homozygous familial hypercholesterolemia (HoFH) has genetic testing confirming two null LDLR alleles (receptor-negative HoFH). Her LDL-C is 680 mg/dL on maximum-dose rosuvastatin plus ezetimibe. Her cardiologist is weighing evolocumab versus lomitapide as add-on therapy. Which of the following best explains why lomitapide is pharmacologically preferred over evolocumab in this specific patient?
A) Lomitapide is preferred because it inhibits PCSK9 secretion from hepatocytes through a distinct intracellular pathway, providing a synergistic reduction in LDL receptor degradation that complements the residual LDL receptor activity present even in receptor-negative HoFH patients
B) Lomitapide is preferred because it upregulates LDL receptor gene transcription via a SREBP-2-independent pathway, increasing de novo LDL receptor synthesis that partially compensates for the null LDLR mutations and restores approximately 30–40% of normal LDL receptor activity regardless of mutation type
C) Lomitapide is preferred because it inhibits MTP (microsomal triglyceride transfer protein) within the hepatocyte endoplasmic reticulum, blocking lipidation of apolipoprotein B-100 required for VLDL assembly and thereby reducing hepatic output of LDL precursor particles through a mechanism entirely independent of LDL receptor function — making it effective regardless of LDLR mutation status
D) Lomitapide is preferred because evolocumab requires intact LDL receptor cycling to exert its effect and is absolutely contraindicated by FDA label in patients with two null LDLR alleles due to documented risk of paradoxical LDL-C elevation when circulating PCSK9 is fully suppressed in the absence of functional receptors
E) Lomitapide is preferred because it directly inhibits hepatic apolipoprotein B-100 translation at the ribosomal level, reducing VLDL and LDL particle number through a post-transcriptional mechanism that bypasses the LDL receptor pathway entirely and has demonstrated superior LDL-C lowering compared to evolocumab in all HoFH genotypes in head-to-head trials
ANSWER: C
Rationale:
In receptor-negative HoFH, both LDLR alleles carry null mutations producing no functional LDL receptor protein. Evolocumab's entire mechanism of action depends on protecting existing LDL receptors from PCSK9-mediated lysosomal degradation — by neutralizing circulating PCSK9, evolocumab allows LDL receptors that would otherwise be destroyed to recycle back to the hepatocyte surface and continue clearing LDL-C from plasma. When no functional LDL receptors exist, there is nothing for evolocumab to protect, and the drug produces minimal or no LDL-C lowering. This mutation-dependent response pattern was demonstrated in the TESLA trial of evolocumab in HoFH, which showed meaningful LDL-C reduction in receptor-defective patients (who retain 1–25% of normal receptor activity) but minimal response in receptor-negative patients. Lomitapide operates through a fundamentally different and entirely receptor-independent mechanism: it inhibits MTP inside the hepatocyte endoplasmic reticulum, blocking the lipidation of apolipoprotein B-100 (apoB-100) required for VLDL particle assembly. Without MTP activity, VLDL cannot be assembled and secreted, reducing hepatic output of the LDL precursor pool and lowering circulating LDL-C by approximately 40–50% from baseline regardless of LDLR genotype. This upstream, receptor-independent mechanism makes lomitapide effective in receptor-negative HoFH patients for whom evolocumab provides no meaningful benefit.
Option A: Option A is incorrect. Lomitapide has no activity at PCSK9. It does not inhibit PCSK9 secretion through any pathway. Lomitapide acts on MTP within the endoplasmic reticulum — a mechanism entirely unrelated to the PCSK9-LDL receptor degradation axis.
Option B: Option B is incorrect. Lomitapide does not upregulate LDL receptor gene transcription through any pathway, SREBP-2-dependent or otherwise. Its mechanism is restricted to MTP inhibition affecting VLDL assembly. It does not restore LDL receptor activity in HoFH patients regardless of mutation type.
Option D: Option D is incorrect. Evolocumab does not carry an FDA label contraindication in receptor-negative HoFH. The prescribing information notes reduced efficacy in patients with two null LDLR alleles — it does not prohibit use or warn of paradoxical LDL-C elevation. The clinical rationale for preferring lomitapide is pharmacodynamic (lack of receptor substrate for evolocumab), not a regulatory contraindication.
Option E: Option E is incorrect. Lomitapide does not inhibit apoB-100 translation at the ribosomal level. That is the mechanism of mipomersen, an antisense oligonucleotide targeting apoB-100 mRNA. Lomitapide's target is MTP protein function within the endoplasmic reticulum — a post-translational mechanism affecting lipid transfer, not translational suppression of apoB-100.
5. A 58-year-old man with stage 4 chronic kidney disease (CKD) (eGFR 22 mL/min/1.73 m²) and established ASCVD has an LDL-C of 96 mg/dL on atorvastatin 40 mg. His nephrologist is concerned about adding ezetimibe given impaired renal function and asks whether dose adjustment is required. Which of the following correctly characterizes ezetimibe pharmacokinetics in this patient and the appropriate clinical decision?
A) Ezetimibe requires significant renal dose adjustment in stage 4 CKD because its active glucuronide metabolite, ezetimibe-glucuronide, undergoes primary renal elimination; at eGFR below 30 mL/min/1.73 m², ezetimibe-glucuronide accumulates to toxic concentrations, and the dose should be reduced to 5 mg daily with LFT (liver function test) monitoring every four weeks
B) Ezetimibe is contraindicated in stage 4 CKD because intestinal NPC1L1 expression is upregulated in uremic patients as a compensatory mechanism for impaired renal cholesterol excretion; blocking upregulated NPC1L1 in this setting causes paradoxical elevation of bile acid synthesis that worsens uremic dyslipidemia
C) Ezetimibe undergoes extensive renal elimination of its parent compound, requiring dose reduction to 5 mg every other day when eGFR falls below 30 mL/min/1.73 m²; however, the SHARP trial demonstrated cardiovascular benefit of simvastatin plus ezetimibe in CKD patients, supporting its use with appropriate dose adjustment in this population
D) Ezetimibe and its active glucuronide metabolite undergo primarily hepatic and biliary elimination with enterohepatic recycling; renal excretion accounts for only a minor fraction of total elimination, and no dose adjustment is required in renal impairment — ezetimibe 10 mg daily is appropriate in stage 4 CKD, supported by the SHARP trial demonstrating LDL-C lowering and cardiovascular benefit of ezetimibe-containing regimens in patients with CKD including those on dialysis
E) Ezetimibe is renally cleared and accumulates significantly in CKD, but the FDA label permits unrestricted use in renal impairment because the accumulated ezetimibe-glucuronide retains full NPC1L1 inhibitory activity without toxicity; the dose remains 10 mg daily but requires concurrent bile acid sequestrant co-administration to prevent uremic enteropathy
ANSWER: D
Rationale:
Ezetimibe undergoes glucuronidation in the intestinal wall and liver to form ezetimibe-glucuronide, its pharmacologically active metabolite. Both ezetimibe and its glucuronide metabolite undergo extensive enterohepatic recycling and are eliminated primarily through biliary and fecal routes. Renal excretion accounts for only approximately 11% of total ezetimibe elimination. As a result, ezetimibe pharmacokinetics are not meaningfully affected by renal impairment, and no dose adjustment is required in any stage of CKD including patients on dialysis. The SHARP trial (Study of Heart and Renal Protection) enrolled 9,270 patients with CKD — including pre-dialysis patients and those on dialysis — and demonstrated that simvastatin 20 mg plus ezetimibe 10 mg reduced LDL-C by approximately 33% and significantly reduced major atherosclerotic events (relative risk reduction 17%) compared to placebo. SHARP provides direct evidence supporting ezetimibe use in CKD without dose modification, and the combination is endorsed for cardiovascular risk reduction in CKD patients by KDIGO (Kidney Disease: Improving Global Outcomes) guidelines. option describes a fabricated pharmacological interaction. option is pharmacokinetically false. There is no requirement for concurrent bile acid sequestrant use with ezetimibe in renal impairment; that recommendation is fabricated.
Option A: Option A is incorrect. Ezetimibe-glucuronide does not undergo primary renal elimination. The drug is predominantly eliminated through biliary and fecal routes via enterohepatic recycling. No dose adjustment is required in CKD, and there is no evidence of toxic accumulation at any stage of renal impairment.
Option B: Option B is incorrect. Ezetimibe is not contraindicated in CKD. There is no established mechanism by which NPC1L1 is upregulated in uremia or by which NPC1L1 blockade causes paradoxical bile acid synthesis elevation that worsens dyslipidemia. This
Option C: Option C is incorrect. Ezetimibe does not undergo extensive renal elimination of the parent compound and does not require dose reduction in CKD. The described dosing regimen of 5 mg every other day has no basis in the FDA label or in established pharmacokinetic data for ezetimibe.
Option E: Option E is incorrect. Ezetimibe is not renally cleared to a significant degree and does not accumulate in CKD. The premise of the
6. A 72-year-old man with established ASCVD and LDL-C of 94 mg/dL on high-intensity atorvastatin plus ezetimibe is a poor candidate for self-injection due to moderate cognitive impairment and limited manual dexterity. His cardiologist is considering inclisiran. Which of the following best describes the mechanism of action and dosing schedule of inclisiran and explains why it is well suited to this patient's situation?
A) Inclisiran is an siRNA (small interfering RNA) agent that silences PCSK9 mRNA within hepatocytes by binding the RISC (RNA-induced silencing complex), preventing translation of PCSK9 protein at its source; it is administered subcutaneously at day 1, month 3, and every six months thereafter, requiring only two injections per year during maintenance — well suited to patients who cannot reliably self-inject because administration can be performed by a healthcare provider during scheduled clinical visits
B) Inclisiran is a humanized monoclonal antibody targeting circulating PCSK9 protein; it prevents PCSK9 from binding the LDL receptor extracellular domain and is administered subcutaneously every two weeks by the patient or a caregiver, offering a mechanism identical to evolocumab but with a longer half-life due to its PEGylated Fc region
C) Inclisiran is an antisense oligonucleotide (ASO) that degrades PCSK9 mRNA in hepatocyte lysosomes via RNase H1 recruitment; it is administered as a monthly subcutaneous injection indefinitely and is preferred in cognitively impaired patients because its monthly schedule aligns with routine office visits, eliminating the need for patient self-administration between visits
D) Inclisiran is a small-molecule oral PCSK9 inhibitor that blocks PCSK9 autocatalytic activation within the hepatocyte endoplasmic reticulum, preventing PCSK9 secretion; it is taken once daily and is preferred in patients with manual dexterity limitations because it eliminates the need for any injection while providing LDL-C lowering equivalent to subcutaneous monoclonal antibodies
E) Inclisiran is a subcutaneous siRNA agent administered once monthly for six months and then quarterly; it silences NPC1L1 mRNA in intestinal enterocytes rather than PCSK9 mRNA in hepatocytes, reducing intestinal cholesterol absorption through a gene-silencing mechanism that complements statin therapy differently from ezetimibe
ANSWER: A
Rationale:
Inclisiran is a synthetic siRNA conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs hepatocyte-specific uptake via the asialoglycoprotein receptor. Once internalized into hepatocytes, inclisiran is incorporated into the RISC, where it directs cleavage and silencing of PCSK9 mRNA, preventing translation of PCSK9 protein. The resulting intracellular depletion of PCSK9 means that newly synthesized LDL receptors recycle normally to the hepatocyte surface rather than being routed to lysosomal degradation — the same net effect as the monoclonal antibody PCSK9 inhibitors, but achieved through gene silencing rather than extracellular protein neutralization. The key clinical advantage of inclisiran's mechanism is its durability: because it silences mRNA production rather than neutralizing circulating protein, its effect persists far longer than the half-life of the drug itself, enabling a dosing schedule of subcutaneous injection on day 1, at month 3, and then every six months. This schedule of two injections per year during maintenance is ideally suited to a patient who cannot reliably self-inject, because all injections can be administered by a healthcare provider in the office during routine visits, eliminating the compliance burden of frequent self-administration.
Option B: Option B is incorrect. Inclisiran is not a monoclonal antibody. It is an siRNA agent — a fundamentally different molecular class. Monoclonal antibodies neutralize circulating PCSK9 protein extracellularly; inclisiran silences PCSK9 mRNA intracellularly within hepatocytes. Inclisiran is not PEGylated and does not have an Fc region.
Option C: Option C is incorrect. Inclisiran is an siRNA agent, not an antisense oligonucleotide (ASO). ASOs recruit RNase H1 to degrade target RNA in a distinct mechanism from RISC-mediated siRNA silencing. Mipomersen is the relevant ASO in lipid pharmacology, targeting apoB-100 mRNA. Inclisiran's dosing schedule is every six months during maintenance — not monthly.
Option D: Option D is incorrect. Inclisiran is a subcutaneous injection, not an oral agent. As of current approval, no oral PCSK9 inhibitor has received FDA approval for clinical use. The described mechanism of blocking PCSK9 autocatalytic activation is not inclisiran's mechanism of action.
Option E: Option E is incorrect. Inclisiran targets PCSK9 mRNA in hepatocytes, not NPC1L1 mRNA in intestinal enterocytes. NPC1L1 is the target of ezetimibe; inclisiran has no activity at NPC1L1 and does not affect intestinal cholesterol absorption. The dosing schedule described is also inaccurate.
7. A 63-year-old man is hospitalized for acute coronary syndrome (ACS) and successfully undergoes percutaneous coronary intervention. His LDL-C on admission is 112 mg/dL despite high-intensity atorvastatin 80 mg. He is discharged on atorvastatin 80 mg plus ezetimibe 10 mg. His cardiologist cites the ODYSSEY OUTCOMES trial to support early addition of alirocumab post-ACS. Which of the following correctly describes the ODYSSEY OUTCOMES trial findings and how they apply to this patient?
A) ODYSSEY OUTCOMES enrolled recent ACS patients on maximally tolerated statin therapy and demonstrated that alirocumab reduced the primary composite endpoint of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization, with a significant reduction in all-cause mortality — a finding not replicated in FOURIER, making ODYSSEY OUTCOMES the stronger trial for guiding PCSK9 inhibitor use in post-ACS patients specifically
B) ODYSSEY OUTCOMES enrolled recent ACS patients and demonstrated that alirocumab reduced the primary composite endpoint; however, all-cause mortality benefit was restricted to the prespecified subgroup with baseline LDL-C above 100 mg/dL — patients with baseline LDL-C between 70 and 100 mg/dL showed no mortality benefit, making alirocumab unjustified in post-ACS patients who achieve LDL-C below 100 mg/dL on background statin therapy
C) ODYSSEY OUTCOMES enrolled patients with ACS occurring within the prior 12 months who were on maximally tolerated statin therapy; alirocumab reduced the primary composite endpoint by a relative 15% and demonstrated a significant reduction in all-cause mortality (3.5% vs. 4.1%, p=0.026) — the first PCSK9 inhibitor trial to show an all-cause mortality signal — supporting early initiation of alirocumab in this post-ACS patient who remains above guideline LDL-C targets on optimized statin plus ezetimibe
D) ODYSSEY OUTCOMES demonstrated benefit only in patients who initiated alirocumab within 48 hours of the index ACS event; patients who started alirocumab more than 72 hours post-ACS showed no significant reduction in the primary composite endpoint, and delayed initiation — such as at hospital discharge — is not supported by the trial evidence
E) ODYSSEY OUTCOMES enrolled ACS patients and demonstrated that alirocumab reduced LDL-C by approximately 62% from baseline, but the reduction in the primary composite cardiovascular endpoint did not reach statistical significance (p=0.09); the trial is cited only for its LDL-C lowering magnitude, not for a demonstrated cardiovascular outcomes benefit, making evolocumab the only PCSK9 inhibitor with proven outcomes benefit based on FOURIER
ANSWER: C
Rationale:
The ODYSSEY OUTCOMES trial enrolled 18,924 patients who had experienced an ACS event (acute MI or unstable angina requiring hospitalization) within the preceding 1 to 12 months and who were on high-intensity or maximum-tolerated statin therapy with LDL-C of 70 mg/dL or above, non-HDL-C of 100 mg/dL or above, or apolipoprotein B of 80 mg/dL or above. Alirocumab reduced the primary composite endpoint — coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization — by a relative 15% (9.5% vs. 11.1%, hazard ratio 0.85, p<0.001). Critically, ODYSSEY OUTCOMES demonstrated a significant reduction in all-cause mortality (3.5% vs. 4.1%, hazard ratio 0.85, p=0.026), the first PCSK9 inhibitor cardiovascular outcomes trial to show this signal — a finding not observed in FOURIER. The mortality benefit was most pronounced in patients with higher baseline LDL-C and those achieving LDL-C below 25 mg/dL on treatment. For this post-ACS patient with LDL-C of 112 mg/dL on atorvastatin 80 mg who now starts ezetimibe at discharge, ODYSSEY OUTCOMES directly supports early alirocumab initiation if LDL-C remains above guideline targets on the combination.
Option A: Option A is incorrect because, while it correctly identifies the all-cause mortality finding, it contains a factual error in the composite endpoint description and overstates the superiority framing relative to FOURIER — both trials demonstrated significant primary composite endpoint reduction; the all-cause mortality signal is what differentiates ODYSSEY OUTCOMES, not a failure of FOURIER to show primary composite benefit.
Option B: Option B is incorrect. The all-cause mortality benefit in ODYSSEY OUTCOMES was observed across the trial population; while higher baseline LDL-C was associated with greater absolute benefit, the trial did not establish a subgroup threshold of 100 mg/dL below which mortality benefit disappears. The baseline LDL-C of this patient (112 mg/dL) would have qualified for enrollment.
Option D: Option D is incorrect. ODYSSEY OUTCOMES did not require alirocumab initiation within 48 hours of the index ACS event. The enrollment window was 1 to 12 months post-ACS. Initiation at hospital discharge — within days of the index event — is consistent with the trial's enrollment criteria and with guideline recommendations for early intensification of lipid-lowering therapy post-ACS.
Option E: Option E is incorrect. ODYSSEY OUTCOMES demonstrated a statistically significant reduction in the primary composite cardiovascular endpoint (p<0.001). The trial is cited for both its outcomes benefit and its all-cause mortality signal. Describing FOURIER as the only PCSK9 inhibitor trial with proven outcomes benefit misrepresents ODYSSEY OUTCOMES, which demonstrated equivalent primary endpoint reduction and a superior mortality signal.
8. A 44-year-old man with a renal transplant on cyclosporine immunosuppression has an LDL-C of 148 mg/dL. His transplant physician adds ezetimibe 10 mg daily. Two weeks later, cyclosporine trough levels are drawn and found to be elevated above the therapeutic range. Which of the following best explains the pharmacokinetic interaction between ezetimibe and cyclosporine and the appropriate clinical management?
A) Cyclosporine inhibits CYP3A4 (cytochrome P450 3A4), the primary enzyme responsible for ezetimibe glucuronidation in the intestinal wall; reduced glucuronidation decreases conversion of ezetimibe to its active metabolite, ezetimibe-glucuronide, resulting in accumulation of parent ezetimibe that competitively inhibits P-glycoprotein efflux of cyclosporine from intestinal enterocytes — raising cyclosporine bioavailability and trough levels
B) Ezetimibe inhibits OATP1B1 (organic anion-transporting polypeptide 1B1) in the hepatic sinusoidal membrane, blocking cyclosporine uptake into hepatocytes; reduced hepatic cyclosporine uptake decreases biliary excretion, prolongs cyclosporine half-life, and elevates trough concentrations — requiring cyclosporine dose reduction and more frequent trough monitoring after ezetimibe initiation
C) Ezetimibe and its glucuronide metabolite inhibit the biliary transporter MRP2 (multidrug resistance-associated protein 2) in hepatocyte canalicular membranes, reducing biliary excretion of cyclosporine and its metabolites; the resulting enterohepatic recirculation of cyclosporine amplifies systemic exposure and elevates trough concentrations without altering cyclosporine hepatic metabolism
D) Cyclosporine inhibits the glucuronidation and biliary transport of ezetimibe-glucuronide, substantially increasing ezetimibe and ezetimibe-glucuronide plasma concentrations; concurrently, ezetimibe increases cyclosporine plasma concentrations through a reciprocal interaction — the FDA label for ezetimibe notes this bidirectional interaction and recommends caution when co-administering ezetimibe with cyclosporine, with close monitoring of both cyclosporine levels and ezetimibe-related adverse effects
E) Ezetimibe competitively inhibits CYP2C8, the enzyme responsible for cyclosporine hydroxylation to its inactive metabolites; reduced CYP2C8-mediated cyclosporine clearance causes parent cyclosporine accumulation, elevated trough levels, and increased nephrotoxicity risk — requiring cyclosporine dose reduction of approximately 30% when ezetimibe is added
ANSWER: D
Rationale:
The interaction between ezetimibe and cyclosporine is bidirectional and is documented in the ezetimibe FDA prescribing information. Cyclosporine inhibits glucuronidation enzymes and biliary transporters involved in ezetimibe-glucuronide elimination, including MRP2 and OATP1B1, resulting in substantially increased plasma concentrations of both ezetimibe and ezetimibe-glucuronide — approximately 3.4-fold and 3.9-fold increases, respectively, have been reported. Concurrently, ezetimibe increases cyclosporine plasma concentrations, likely through inhibition of P-glycoprotein and/or OATP1B1-mediated hepatic uptake and biliary cycling of cyclosporine. The FDA label for ezetimibe explicitly flags this interaction and recommends caution when ezetimibe is co-administered with cyclosporine, with close monitoring of cyclosporine concentrations and clinical assessment for increased ezetimibe exposure. In transplant patients on cyclosporine, the increased ezetimibe exposure is generally well tolerated but the elevated cyclosporine levels require therapeutic drug monitoring with possible dose adjustment. This interaction is a clinically important consideration in renal transplant recipients, in whom cyclosporine toxicity (nephrotoxicity, hypertension) can cause graft injury. option is pharmacokinetically inaccurate. option captures part of the mechanism but misrepresents the interaction as unidirectional and omits the FDA label's caution regarding elevated ezetimibe concentrations. option also omits the important bidirectional nature of the interaction.
Option A: Option A is incorrect. Ezetimibe is not glucuronidated by CYP3A4; glucuronidation is a Phase II reaction catalyzed by UGT (UDP-glucuronosyltransferase) enzymes, not CYP enzymes. Furthermore, cyclosporine does not elevate its own bioavailability through P-glycoprotein inhibition by ezetimibe through the mechanism described. The mechanistic description in this
Option B: Option B is incorrect in its framing. While OATP1B1 inhibition is part of the ezetimibe-cyclosporine interaction, the primary documented clinical consequence of the interaction involves elevated concentrations of both drugs — not simply reduced cyclosporine hepatic uptake and prolonged half-life. The
Option C: Option C is incorrect. While MRP2 may be involved in ezetimibe-glucuronide biliary excretion, the described mechanism of MRP2 inhibition by ezetimibe causing cyclosporine enterohepatic recirculation is not established pharmacokinetic evidence for this interaction. The
Option E: Option E is incorrect. Cyclosporine is not primarily metabolized by CYP2C8. Cyclosporine metabolism is predominantly mediated by CYP3A4 in the liver and intestine. Ezetimibe is not a clinically significant CYP2C8 inhibitor, and this mechanism does not account for the observed cyclosporine level elevation.
9. A 34-year-old woman with HoFH and receptor-defective LDLR mutations has an LDL-C of 420 mg/dL on rosuvastatin 40 mg plus ezetimibe plus evolocumab, and she undergoes LDL apheresis every two weeks. Her lipidologist is considering adding lomitapide or mipomersen. Which of the following best distinguishes the mechanisms of lomitapide and mipomersen and guides the selection between them?
A) Lomitapide and mipomersen share an identical mechanism — both inhibit MTP in the hepatocyte endoplasmic reticulum — but differ in route of administration: lomitapide is an oral capsule taken daily while mipomersen is a weekly subcutaneous injection; mipomersen is preferred because subcutaneous administration avoids the gastrointestinal adverse effects of oral MTP inhibition
B) Mipomersen is an antisense oligonucleotide (ASO) that recruits RNase H1 to degrade hepatic apolipoprotein B-100 mRNA, reducing apoB-100 protein synthesis and lowering VLDL and LDL particle production; lomitapide is an oral small-molecule MTP inhibitor that blocks lipidation of apoB-100 within the endoplasmic reticulum, preventing VLDL assembly; both agents reduce LDL-C by upstream suppression of hepatic LDL particle output through distinct molecular mechanisms, and both carry REMS (Risk Evaluation and Mitigation Strategy) programs due to hepatotoxicity risk, including potential hepatic steatosis and elevated transaminases
C) Lomitapide is an ASO targeting MTP mRNA in hepatocytes; mipomersen is a small-molecule inhibitor of apoB-100 translation elongation at the ribosomal level; both are administered orally and have equivalent hepatotoxicity profiles; mipomersen is preferred in patients already on evolocumab because its ribosomal mechanism is pharmacologically synergistic with PCSK9 inhibition in a way that MTP mRNA silencing is not
D) Mipomersen inhibits NPC1L1 in intestinal enterocytes through an antisense mechanism, reducing cholesterol absorption and complementing ezetimibe at the same intestinal target but with greater potency; lomitapide inhibits hepatic cholesterol ester transfer protein (CETP), redistributing cholesterol from LDL to HDL particles; the two agents address different lipoprotein fractions and are therefore additive in HoFH
E) Lomitapide is preferred over mipomersen in patients already receiving evolocumab because lomitapide's MTP inhibition acts upstream of the LDL receptor pathway and produces additive LDL-C lowering in receptor-defective HoFH patients, while mipomersen's apoB-100 ASO mechanism has been shown to be pharmacologically antagonistic with PCSK9 inhibition in receptor-defective patients due to competitive binding at the asialoglycoprotein receptor used by both agents for hepatocyte delivery
ANSWER: B
Rationale:
Mipomersen and lomitapide are both approved for HoFH as adjuncts to maximally tolerated lipid-lowering therapy and LDL apheresis, but they act through entirely distinct molecular mechanisms. Mipomersen is a second-generation antisense oligonucleotide (ASO) that binds apoB-100 mRNA in hepatocytes and recruits RNase H1 to cleave the RNA-ASO duplex, degrading apoB-100 mRNA and reducing the amount of apoB-100 protein available for VLDL assembly. Lower apoB-100 production means fewer VLDL particles are secreted, which reduces the LDL precursor pool and lowers circulating LDL-C. Lomitapide is an oral small-molecule inhibitor of MTP (microsomal triglyceride transfer protein), a heterodimeric protein in the hepatocyte endoplasmic reticulum that transfers triglycerides onto nascent apoB-100, a lipidation step required for VLDL particle assembly and secretion. Without functional MTP activity, apoB-100 cannot be lipidated, VLDL cannot be assembled, and hepatic LDL particle output is suppressed. Both mechanisms are receptor-independent and reduce LDL-C in HoFH regardless of LDLR genotype. Both agents carry REMS programs due to the risk of hepatotoxicity — specifically hepatic steatosis and transaminase elevation — which require enrollment in REMS and regular monitoring of liver function. In clinical practice, lomitapide (oral, daily) is more commonly used than mipomersen (subcutaneous weekly injection) in the United States, where mipomersen has more limited utilization. option describes a fabricated interaction.
Option A: Option A is incorrect. Lomitapide and mipomersen do not share an identical mechanism. Lomitapide inhibits MTP protein function; mipomersen degrades apoB-100 mRNA through RNase H1 recruitment. These are distinct molecular targets and distinct mechanistic classes (small-molecule enzyme inhibitor vs. antisense oligonucleotide).
Option C: Option C is incorrect. Lomitapide is not an ASO; it is an oral small-molecule MTP protein inhibitor. Mipomersen is not a ribosomal elongation inhibitor; it is an ASO acting on apoB-100 mRNA through RNase H1. Neither agent is administered orally as both — mipomersen is subcutaneous. There is no established pharmacological antagonism between mipomersen and PCSK9 inhibitors through the asialoglycoprotein receptor.
Option D: Option D is incorrect. Mipomersen does not target NPC1L1 and has no activity at intestinal cholesterol absorption. It targets hepatic apoB-100 mRNA. Lomitapide does not inhibit CETP; CETP inhibition is the mechanism of agents such as anacetrapib and obicetrapib, which are in a separate drug class from MTP inhibitors.
Option E: Option E is incorrect. There is no established pharmacological antagonism between mipomersen and PCSK9 inhibitors through the asialoglycoprotein receptor. Inclisiran uses GalNAc conjugation for asialoglycoprotein receptor-mediated hepatic uptake, but mipomersen uses a different delivery mechanism and does not compete with PCSK9 inhibitors at this receptor. This
10. A 69-year-old woman with prior MI, prior ischemic stroke, and type 2 diabetes has an LDL-C of 62 mg/dL on rosuvastatin 40 mg plus ezetimibe. Her cardiologist notes that current ACC/AHA guidelines classify her as very high-risk ASCVD with a guideline LDL-C target of less than 55 mg/dL. She asks whether adding a PCSK9 inhibitor is justified and whether her LDL-C can be driven too low safely. Which of the following most accurately addresses both questions?
A) Adding a PCSK9 inhibitor is not guideline-supported because both FOURIER and ODYSSEY OUTCOMES excluded patients with LDL-C below 70 mg/dL at enrollment; this patient's current LDL-C of 62 mg/dL falls below both trials' enrollment thresholds, meaning no outcomes evidence exists for PCSK9 inhibitor benefit at her baseline LDL-C, and addition would be off-label use without supporting data
B) Safety data from FOURIER and ODYSSEY OUTCOMES demonstrate a J-shaped relationship between achieved LDL-C and cardiovascular outcomes, with paradoxically increased rates of hemorrhagic stroke and new-onset diabetes at achieved LDL-C below 25 mg/dL; adding a PCSK9 inhibitor to push LDL-C below 55 mg/dL is therefore contraindicated if on-treatment LDL-C is projected to fall below this safety floor
C) Current ACC/AHA guidelines support a less than 55 mg/dL LDL-C target only for patients with a single qualifying ASCVD event; patients with multiple major ASCVD events like this patient require an individualized target negotiated with a lipidologist and are not captured by the standard very high-risk ACC/AHA framework, making PCSK9 inhibitor addition a clinical judgment decision rather than a guideline-driven recommendation
D) PCSK9 inhibitor addition is guideline-supported only after the patient has failed at least two different high-intensity statin regimens and two non-statin agents sequentially; because this patient has not tried a second statin, initiation of evolocumab or alirocumab is premature and not consistent with the step-therapy requirements established in the 2018 ACC/AHA cholesterol guideline
E) Current ACC/AHA guidelines define very high-risk ASCVD as the presence of multiple major ASCVD events or one major ASCVD event with multiple high-risk conditions — this patient with prior MI, prior stroke, and diabetes meets very high-risk criteria; the guideline-recommended LDL-C target of less than 55 mg/dL supports adding a PCSK9 inhibitor, and cardiovascular outcomes data from FOURIER and ODYSSEY OUTCOMES — including patients achieving on-treatment LDL-C below 20 mg/dL — demonstrate no increase in hemorrhagic stroke, neurocognitive effects, or new-onset diabetes at very low achieved LDL-C levels, supporting the safety of aggressive LDL-C lowering in this patient
ANSWER: E
Rationale:
The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol defines very high-risk ASCVD as patients with a history of multiple major ASCVD events or one major ASCVD event in the presence of multiple high-risk conditions. Major ASCVD events include recent ACS, prior MI, prior stroke, and symptomatic peripheral arterial disease. High-risk conditions include diabetes mellitus, hypertension, CKD, current smoking, elevated LDL-C despite maximally tolerated therapy, and age above 65. This patient — with prior MI, prior ischemic stroke, and type 2 diabetes — meets very high-risk criteria on the basis of two major ASCVD events alone, independent of her comorbidities. For very high-risk patients, the guideline recommends an LDL-C target of less than 55 mg/dL and supports the addition of ezetimibe and/or a PCSK9 inhibitor when LDL-C remains above target on maximally tolerated statin therapy. Regarding safety at very low LDL-C levels, cardiovascular outcomes data from both FOURIER (median on-treatment LDL-C 30 mg/dL, with subgroups achieving below 20 mg/dL) and ODYSSEY OUTCOMES (with patients achieving LDL-C below 25 mg/dL) demonstrated no significant increase in hemorrhagic stroke, neurocognitive impairment, or new-onset diabetes at very low achieved LDL-C. The evidence supports the principle that lower LDL-C is better across the range achievable with current therapies, with no established safety floor from clinical trial data.
Option A: Option A is incorrect. While FOURIER enrolled patients with LDL-C of 70 mg/dL or above and ODYSSEY OUTCOMES enrolled patients with LDL-C of 70 mg/dL or above at baseline, the guideline target of less than 55 mg/dL represents the treatment goal for very high-risk patients — it is not derived from the enrollment thresholds of these trials. The current LDL-C of 62 mg/dL above the 55 mg/dL target supports intensification; enrollment thresholds do not define the floor of clinical eligibility for treatment.
Option B: Option B is incorrect. Neither FOURIER nor ODYSSEY OUTCOMES demonstrated a J-shaped relationship between achieved LDL-C and adverse outcomes. Safety analyses in both trials, including pre-specified analyses of patients achieving LDL-C below 25 mg/dL, showed no increase in hemorrhagic stroke, neurocognitive effects, or new-onset diabetes. A safety floor of 25 mg/dL is not established by these trials or by current guidelines.
Option C: Option C is incorrect. The ACC/AHA very high-risk ASCVD category applies to patients with multiple major ASCVD events — this patient's prior MI and prior stroke alone qualify her, independent of any additional comorbidities. The guideline does not restrict the less than 55 mg/dL target to single-event patients; it applies to the very high-risk category as defined, which this patient clearly meets.
Option D: Option D is incorrect. The 2018 ACC/AHA guideline does not require sequential failure of two statin regimens and two non-statin agents before PCSK9 inhibitor initiation. The guideline supports PCSK9 inhibitor addition in very high-risk patients not at LDL-C goal on maximally tolerated statin plus ezetimibe. There is no mandated step-therapy sequence requiring a second statin trial before PCSK9 inhibitor use.
11. A 51-year-old man reports severe myalgia on three different statins, including low-dose rosuvastatin 5 mg. Creatine kinase levels are normal. His cardiologist concludes he has statin intolerance and discontinues statin therapy. His LDL-C off statins is 171 mg/dL. He has no established ASCVD but has a 10-year ASCVD risk of 14%. His cardiologist initiates ezetimibe monotherapy. Which of the following best describes the evidence base for ezetimibe monotherapy in this setting and the expected magnitude of LDL-C reduction?
A) Ezetimibe monotherapy is not supported by guideline recommendations for primary prevention because all major cardiovascular outcomes trials of ezetimibe — including SHARP and IMPROVE-IT — enrolled only patients with established ASCVD or CKD; use of ezetimibe monotherapy in a primary prevention patient without established ASCVD is off-label and has no outcomes evidence, making bile acid sequestrants the preferred non-statin alternative in guideline-concordant primary prevention
B) Ezetimibe monotherapy reduces LDL-C by approximately 15–22% from baseline as a single agent; the SHARP trial demonstrated cardiovascular event reduction with simvastatin plus ezetimibe in CKD patients but not in non-CKD primary prevention patients, and ezetimibe monotherapy has no dedicated cardiovascular outcomes trial in statin-intolerant patients; nevertheless, guideline recommendations support its use in statin-intolerant patients with elevated ASCVD risk based on its LDL-C lowering efficacy and favorable safety profile
C) Ezetimibe monotherapy reduces LDL-C by approximately 50–55% as a single agent through its combined NPC1L1 blockade and secondary PCSK9 suppression; the magnitude of LDL-C reduction is equivalent to high-intensity statin therapy, making ezetimibe a pharmacologically adequate substitute for rosuvastatin or atorvastatin in statin-intolerant patients with LDL-C above 160 mg/dL
D) The IMPROVE-IT trial demonstrated that ezetimibe monotherapy — without background statin — reduced cardiovascular events by 24% relative to placebo in post-ACS statin-intolerant patients; this is the primary outcomes evidence cited by guidelines for ezetimibe monotherapy in patients who cannot tolerate any statin, and the 14% 10-year ASCVD risk in this patient meets the risk threshold for initiating therapy based on IMPROVE-IT enrollment criteria
E) Ezetimibe monotherapy produces LDL-C reductions of approximately 35–40% and has demonstrated mortality benefit as a single agent in the SEAS trial (Simvastatin and Ezetimibe in Aortic Stenosis) independent of the statin component; current guidelines recommend ezetimibe monotherapy as first-line non-statin therapy in all patients with LDL-C above 160 mg/dL and 10-year ASCVD risk above 10%, prior to considering bile acid sequestrants or PCSK9 inhibitors
ANSWER: B
Rationale:
Ezetimibe monotherapy, without background statin therapy, reduces LDL-C by approximately 15–22% from baseline. This is substantially less than the 38–55% LDL-C reduction achieved with high-intensity statin monotherapy, and less than the additive 15–25% additional reduction ezetimibe contributes when used with a statin. The mechanism is unchanged — NPC1L1 blockade at the intestinal brush border — but without statin-mediated SREBP-2 activation to drive compensatory LDL receptor upregulation, the liver's counter-regulatory response is less robust, yielding a more modest LDL-C reduction. For this patient's LDL-C of 171 mg/dL, ezetimibe monotherapy might be expected to reduce LDL-C to approximately 133–145 mg/dL — a meaningful reduction though not sufficient to reach an LDL-C goal of less than 100 mg/dL for an intermediate-risk primary prevention patient. Regarding outcomes evidence, ezetimibe monotherapy does not have a dedicated cardiovascular outcomes trial in statin-intolerant patients. The SHARP trial enrolled CKD patients (not primary prevention patients) on simvastatin-ezetimibe combination therapy. IMPROVE-IT enrolled post-ACS patients on background simvastatin — it was an add-on trial, not a monotherapy trial. Despite the absence of dedicated monotherapy outcomes data, current ACC/AHA guidelines and European guidelines support ezetimibe use in statin-intolerant patients who require LDL-C lowering based on its established efficacy and excellent tolerability. option given its LDL-C lowering efficacy and safety profile. The claim that bile acid sequestrants are the preferred guideline-concordant alternative is not accurate.
Option A: Option A is incorrect. Ezetimibe use in primary prevention statin-intolerant patients is guideline-supported, not off-label. ACC/AHA guidelines specifically address non-statin therapy alternatives in statin-intolerant patients, and ezetimibe is listed as a reasonable
Option C: Option C is incorrect. Ezetimibe monotherapy does not reduce LDL-C by 50–55%. That magnitude of reduction is associated with high-intensity statin monotherapy or PCSK9 inhibitor monotherapy. Ezetimibe monotherapy reduces LDL-C by approximately 15–22% as a single agent. Ezetimibe also does not suppress PCSK9 — that claim is mechanistically incorrect.
Option D: Option D is incorrect. IMPROVE-IT did not study ezetimibe monotherapy. It enrolled post-ACS patients on background simvastatin 40 mg and randomized them to add ezetimibe or placebo — it was an add-on trial demonstrating incremental benefit of ezetimibe on top of statin, not a standalone ezetimibe outcomes trial in statin-intolerant patients.
Option E: Option E is incorrect. Ezetimibe monotherapy does not produce LDL-C reductions of 35–40%; that figure substantially overestimates monotherapy efficacy. The SEAS trial studied simvastatin plus ezetimibe in aortic stenosis — it was a combination trial, and any reported outcomes cannot be attributed to ezetimibe alone. Ezetimibe monotherapy has not demonstrated mortality benefit as a single agent in any major trial.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.